Guidance for Industry: Fast Track Drug Development Programs - Designation, Development, and Application Review
Extension without change of a currently approved collection
No
Regular
Approved without change
09/29/2008
08/28/2008
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
09/30/2011
36 Months From Approved
09/30/2008
137
0
114
10,620
0
8,720
0
0
0
This guidance is intended to articulate how FDA plans to work with sponsors to achieve expedited development and rapid review of new drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs for the condition. The guidance also meets the requirements of section 112 of the Food and Drug Administration Modernization Act of 1997, which amended the Federal Food, Drug and Cosmetic Act (21 U.S.C. 351 et seq.) by adding new section 506 ("Fast Track Products").
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.